Print Page  |  Close Window

Investor Center

Recent Press Releases

Neuralstem Announces Last Subject Enrolled in Phase 2 Trial with NSI-189 for Major Depressive Disorder

02/16/17 - - Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system thera... More

Neuralstem to Present at BIO CEO & Investor Conference

02/13/17 - GERMANTOWN, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announces tha... More

Neuralstem Announces a 1-for-13 Reverse Stock Split

01/06/17 - GERMANTOWN, Md., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announc... More

Upcoming Events


There are currently no events scheduled.